Company research
Syros Pharmaceuticals, Inc.
CIK 1556263Updated Oct 6, 2026
SecuritySYRS · OTC · equity
Name history
LS22, Inc. · through Aug 22, 2012
SYRS price & chart
Loading TradingView…
OTC:SYRS on TradingView ↗About the company
Syros’ mission was to develop new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros had developed tamibarotene, an oral selective RARα agonist, in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.
In the news
No coverage from other publishers is available.
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2024 | Q3 2023 | Q3 2022 | Q2 2024 | Q2 2023 | Q2 2022 | Q1 2024 | Q1 2023 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 84,995,000Source | 147,795,000Source | 284,725,000Source | 106,722,000Source | 180,982,000Source | 126,234,000Source | 134,728,000Source | 205,323,000Source | 168,174,000Source | 244,486,000Source | 182,935,000Source | 213,250,000Source |
| Property, Plant and Equipment, NetUSD | 6,308,000Source | 7,614,000Source | 12,062,000Source | 6,633,000Source | 10,299,000Source | 11,994,000Source | 6,964,000Source | 10,950,000Source | 7,298,000Source | 11,353,000Source | 12,844,000Source | 14,213,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 58,275,000Source | 112,219,000Source | 171,532,000Source | 78,964,000Source | 115,442,000Source | 59,064,000Source | 83,523,000Source | 104,765,000Source | 139,526,000Source | 167,467,000Source | 92,302,000Source | 173,984,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 7,000Source |
| Assets, CurrentUSD | 63,931,000Source | 122,515,000Source | 252,305,000Source | 84,921,000Source | 152,630,000Source | 91,945,000Source | 112,202,000Source | 173,644,000Source | 144,980,000Source | 211,392,000Source | 136,585,000Source | 178,557,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,656,000Source | 8,631,000Source | 6,053,000Source | 5,957,000Source | 6,892,000Source | 3,369,000Source | 3,898,000Source | 6,076,000Source | 5,454,000Source | 7,394,000Source | 3,237,000Source | 2,242,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,271,000Source | 12,464,000Source | 13,464,000Source | 11,589,000Source | 12,731,000Source | 13,687,000Source | 11,893,000Source | 12,986,000Source | 12,185,000Source | 13,231,000Source | 14,104,000Source | 14,831,000Source |
| Other Assets, NoncurrentUSD | 1,366,000Source | 2,113,000Source | 3,667,000Source | 1,460,000Source | 2,229,000Source | 5,316,000Source | 1,550,000Source | 4,647,000Source | 1,592,000Source | 5,348,000Source | 2,941,000Source | 1,966,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 27,000Source | 21,000Source | 20,000Source | 26,000Source | 20,000Source | 62,000Source | 26,000Source | 20,000Source | 26,000Source | 20,000Source | 61,000Source | 56,000Source |
| Retained Earnings (Accumulated Deficit)USD | -756,238,000Source | -658,423,000Source | -553,459,000Source | -749,842,000Source | -618,280,000Source | -523,206,000Source | -726,515,000Source | -582,022,000Source | -722,807,000Source | -558,233,000Source | -463,579,000Source | -377,021,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | -226,000Source | — | 49,000Source | -313,000Source | — | 263,000Source | — | 102,000Source | -79,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -11,123,000Source | 36,302,000Source | 129,171,000Source | -6,352,000Source | 73,239,000Source | 31,019,000Source | 15,057,000Source | 106,753,000Source | 16,662,000Source | 127,736,000Source | 85,218,000Source | 90,553,000Source |
| Additional Paid in Capital, Common StockUSD | 745,088,000Source | 694,704,000Source | 682,836,000Source | 743,464,000Source | 691,450,000Source | 554,476,000Source | 741,546,000Source | 688,492,000Source | 739,443,000Source | 685,847,000Source | 548,815,000Source | 467,518,000Source |
| Liabilities and EquityUSD | 84,995,000Source | 147,795,000Source | 284,725,000Source | 106,722,000Source | 180,982,000Source | 126,234,000Source | 134,728,000Source | 205,323,000Source | 168,174,000Source | 244,486,000Source | 182,935,000Source | 213,250,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,392,000Source | 28,394,000Source | 38,424,000Source | 24,521,000Source | 28,375,000Source | 38,927,000Source | 37,303,000Source | 23,551,000Source | 36,681,000Source | 30,778,000Source | 31,508,000Source | 28,624,000Source |
| Operating Lease, Liability, CurrentUSD | 2,584,000Source | 2,241,000Source | 1,932,000Source | 2,495,000Source | 2,161,000Source | 1,860,000Source | 2,409,000Source | 2,083,000Source | 2,324,000Source | 2,006,000Source | 1,720,000Source | 1,463,000Source |
| Accounts Payable, CurrentUSD | 9,646,000Source | 2,855,000Source | 13,017,000Source | 7,469,000Source | 6,693,000Source | 6,124,000Source | 11,346,000Source | 2,795,000Source | 11,544,000Source | 6,411,000Source | 3,692,000Source | 3,603,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,561,000Source | 19,144,000Source | 21,385,000Source | 17,232,000Source | 19,726,000Source | 21,887,000Source | 17,887,000Source | 20,295,000Source | 18,528,000Source | 20,851,000Source | 22,858,000Source | 24,578,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | 108,300,000Source | — | — | — | — | 174,000,000Source |
| Deferred Revenue, CurrentUSD | — | 139,000Source | 1,625,000Source | — | 2,185,000Source | 3,591,000Source | — | 3,245,000Source | — | 4,330,000Source | 10,181,000Source | 12,209,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 1,667,000Source | — | — | — | 6,667,000Source | 11,667,000Source | 1,667,000Source | 6,667,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 41,081,000Source | 39,406,000Source | 40,514,000Source | 40,934,000Source | 40,930,000Source | 33,968,000Source | 29,708,000Source | 39,117,000Source | 34,556,000Source | 40,649,000Source | 40,257,000Source | 39,551,000Source |
cash flow · annual statements
| Line item | Q4 2023 | Q4 2022 | Q3 2024 | Q3 2023 | Q2 2024 | Q2 2023 | Q1 2024 | Q1 2023 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -3,708,000Source | -23,789,000Source | -164,574,000Source | -94,654,000Source | -86,558,000Source | -84,038,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 334,000Source | 638,000Source | 2,252,000Source | 2,706,000Source | 2,758,000Source | 2,774,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,103,000Source | 2,645,000Source | 10,434,000Source | 11,410,000Source | 10,354,000Source | 10,939,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | -7,000Source | -19,993,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -198,000Source | -3,616,000Source | 5,133,000Source | 2,766,000Source | 48,000Source | -1,057,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -31,098,000Source | -36,901,000Source | -109,707,000Source | -123,065,000Source | -99,540,000Source | -57,364,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -24,640,000Source | -25,748,000Source | 37,337,000Source | 67,185,000Source | -52,653,000Source | 46,664,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 235,000Source | 272,000Source | 1,241,000Source | 1,245,000Source | 3,336,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -265,000Source | -53,000Source | 43,462,000Source | 131,045,000Source | 70,511,000Source | 142,953,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -56,003,000Source | -62,702,000Source | -28,908,000Source | 75,165,000Source | -81,682,000Source | 132,253,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 60,394,000Source | 115,305,000Source | 81,083,000Source | 118,528,000Source | 85,642,000Source | 107,851,000Source | 141,645,000Source | 170,553,000Source | 95,388,000Source | 177,070,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,209,000Source | 1,053,000Source | 4,552,000Source | 3,408,000Source | 3,191,000Source | 1,505,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,625,000Source | 3,255,000Source | 1,803,000Source | 2,814,000Source | 2,103,000Source | 2,645,000Source | 10,434,000Source | 11,410,000Source | 10,354,000Source | 10,939,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | 108,300,000Source | — | — | — | — | 174,000,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| General and Administrative ExpenseUSD | — | — | 5,655,000Source | 7,764,000Source | 5,463,000Source | 7,225,000Source | 6,266,000Source | 7,405,000Source | 28,282,000Source | 29,299,000Source | 23,036,000Source | 21,325,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 3,000Source | 1,000Source | 4,000Source |
| Investment Income, InterestUSD | — | — | 793,000Source | 1,633,000Source | 1,085,000Source | 2,125,000Source | 1,546,000Source | 1,775,000Source | 6,816,000Source | 2,132,000Source | 87,000Source | 426,000Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,396,000Source | -40,143,000Source | -23,327,000Source | -36,258,000Source | -3,708,000Source | -23,789,000Source | -164,574,000Source | -94,654,000Source | -86,558,000Source | -84,038,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -6,396,000Source | -40,143,000Source | -23,327,000Source | -36,258,000Source | -3,708,000Source | -23,789,000Source | -164,574,000Source | -94,654,000Source | -86,558,000Source | -84,038,000Source |
| Operating ExpensesUSD | — | — | 26,182,000Source | 38,398,000Source | 27,416,000Source | 36,833,000Source | 30,921,000Source | 36,166,000Source | 138,924,000Source | 150,753,000Source | 122,908,000Source | 97,390,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 66,000Source | 76,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 1,357,000Source | — | — | 11,896,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 1,000Source | 200,000Source | 1,100,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2023 | Q4 2022 | Q3 2024 | Q3 2023 | Q2 2024 | Q2 2023 | Q1 2024 | Q1 2023 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 3,762,000Source | — | 2,833,000Source | — | 2,954,000Source | 9,936,000Source | 14,880,000Source | 23,488,000Source | 15,093,000Source |
| Operating Income (Loss)USD | — | — | -26,182,000Source | -34,636,000Source | -27,416,000Source | -34,000,000Source | -30,921,000Source | -33,212,000Source | -128,988,000Source | -135,873,000Source | -99,420,000Source | -82,297,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 3,000Source | 1,000Source | 4,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,396,000Source | -40,143,000Source | -23,327,000Source | -36,258,000Source | -3,708,000Source | -23,789,000Source | -164,574,000Source | -94,654,000Source | -86,558,000Source | -84,038,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -1.43Source | -0.59Source | -1.3Source | -0.1Source | -0.85Source | -5.81Source | -7.49Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -1.43Source | -0.59Source | -1.3Source | -0.1Source | -0.85Source | -5.81Source | -7.49Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 39,335,772Source | 27,990,558Source | 39,269,434Source | 27,913,448Source | 38,978,046Source | 27,842,218Source | 28,325,779Source | 12,631,968Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 39,335,772Source | 27,990,558Source | 39,269,434Source | 27,913,448Source | 38,978,046Source | 27,842,218Source | 28,325,779Source | 12,631,968Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 3,000Source | 1,000Source | 4,000Source |
| General and Administrative ExpenseUSD | — | — | 5,655,000Source | 7,764,000Source | 5,463,000Source | 7,225,000Source | 6,266,000Source | 7,405,000Source | 28,282,000Source | 29,299,000Source | 23,036,000Source | 21,325,000Source |
| Interest ExpenseUSD | — | — | — | 1,303,000Source | 1,382,000Source | 1,278,000Source | 1,307,000Source | 1,217,000Source | 5,127,000Source | 4,134,000Source | 3,907,000Source | 1,792,000Source |
| Investment Income, InterestUSD | — | — | 793,000Source | 1,633,000Source | 1,085,000Source | 2,125,000Source | 1,546,000Source | 1,775,000Source | 6,816,000Source | 2,132,000Source | 87,000Source | 426,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -6,396,000Source | -40,143,000Source | -23,327,000Source | -36,258,000Source | -3,708,000Source | -23,789,000Source | -164,574,000Source | -94,654,000Source | -86,558,000Source | -84,038,000Source |
| Operating ExpensesUSD | — | — | 26,182,000Source | 38,398,000Source | 27,416,000Source | 36,833,000Source | 30,921,000Source | 36,166,000Source | 138,924,000Source | 150,753,000Source | 122,908,000Source | 97,390,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 66,000Source | 76,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 20,527,000Source | 28,280,000Source | 21,953,000Source | 29,608,000Source | 24,655,000Source | 28,761,000Source | 108,153,000Source | 111,944,000Source | 99,872,000Source | 76,065,000Source |
| Interest Expense (non-operating) | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
Filing attachments
d926755dex991.htm · 8-K · 2025-02-28
EX-99.1 2 d926755dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration CAMBRIDGE, Mass., February 28, 2025 - Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspe…
Read attachment ↗